HBS sets sights on US human trial for platelet preservation technology
This article was originally published in Clinica
After completing a second in vitro study of its technology for extending the shelf life of blood platelets, Human BioSystems (HBS) is preparing to submit an application to the US FDA within the next few months to test the method in human infusion studies.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.